1 |
Agus DB, Akita RW, Fox WD, et al (2002). Targeting ligandactivated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2, 127-37.
DOI
|
2 |
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100, 3983-8.
DOI
|
3 |
Amiri-Kordestani L, Blumenthal GM, Xu QC, et al (2014). FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res, 20, 4436-41.
DOI
|
4 |
Anderson NG, Ahmad T, Chan K, et al (2001). ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer, 94, 774-82.
DOI
|
5 |
Baselga J (2001). Phase I and II clinical trials of trastuzumab. Ann Oncol, 12, 49-55.
|
6 |
Basu A (2008). Molecular targets of breast cancer: AKTing in concert. Breast Cancer: Basic Clin Res, 2, 11-6.
|
7 |
Bouchalova K, Cizkova M, Cwiertka K, et al (2009). Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical papers of the Medical Faculty of the University Palacky. Olomouc, Czechoslovakia, 153, 13-7.
DOI
|
8 |
Brand TM, Iida M, Li CR, et al (2011). The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine, 66, 419-32.
|
9 |
Brennan M, Lim B (2015). The actual role of receptors as cancer markers, biochemical and clinical aspects: receptors in breast cancer. Adv Exp Med Biol, 867, 327-37.
DOI
|
10 |
Burgess AW, Henis YI, Hynes NE, et al (2014). EGF receptor family: twisting targets for improved cancer therapies. Growth Factors, 32, 74-81.
DOI
|
11 |
Canonici A, Gijsen M, Mullooly M, et al (2013). Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget, 4, 1592-605.
DOI
|
12 |
Carpenter G, Cohen S (1979). Epidermal growth factor. Annu Rev Biochem, 48, 193-216.
DOI
|
13 |
Cho HS, Mason K, Ramyar KX, et al (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421, 756-60.
DOI
|
14 |
Dhomen NS, Mariadason J, Tebbutt N, et al (2012). Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog, 17, 31-50.
DOI
|
15 |
Dick JE (2003). Breast cancer stem cells revealed. Proc Natl Acad Sci USA, 100, 3547-9.
DOI
|
16 |
Dimitrakopoulos FI, Kottorou A, Antonacopoulou AG, et al (2015). Early-stage breast cancer in the elderly: confronting an old clinical problem. J Breast Cancer, 18, 207-17.
DOI
|
17 |
Ettinger DS (2006). Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 11, 358-73.
DOI
|
18 |
Dontu G (2008). Breast cancer stem cell markers - the rocky road to clinical applications. Breast cancer research : BCR, 10, 110.
DOI
|
19 |
Dragu DL, Necula LG, Bleotu C, et al (2015). Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells, 7, 1185-201.
|
20 |
Ennis BW, Lippman ME, Dickson RB (1991). The EGF receptor system as a target for antitumor therapy. Cancer Invest, 9, 553-62.
DOI
|
21 |
Fan Z, Baselga J, Masui H, et al (1993). Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res, 53, 4637-42.
|
22 |
Foy KC, Wygle RM, Miller MJ, et al (2013). Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol, 191, 217-27.
DOI
|
23 |
Gancberg D, Jarvinen T, di Leo A, et al (2002). Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat, 74, 113-20.
DOI
|
24 |
Geyer CE, Forster J, Lindquist D, et al (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355, 2733-43.
DOI
|
25 |
Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67.
DOI
|
26 |
Huang L, Fu L (2015). Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B, 5, 390-401.
DOI
|
27 |
Gingras AC, Kennedy SG, O'Leary MA, et al (1998). 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev, 12, 502-13.
DOI
|
28 |
Harris RC, Chung E, Coffey RJ (2003). EGF receptor ligands. Exp Cell Res, 284, 2-13.
DOI
|
29 |
Herbst RS, Bunn PA, Jr. (2003). Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 9, 5813-24.
|
30 |
Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.
DOI
|
31 |
Iqbal N, Iqbal N (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int, 2014, 852748.
|
32 |
Kamath S, Buolamwini JK (2006). Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Res Reviews, 26, 569-94.
DOI
|
33 |
Kanematsu T, Yano S, Uehara H, et al (2003). Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res, 13, 289-98.
DOI
|
34 |
Knowlden JM, Hutcheson IR, Jones HE, et al (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 144, 1032-44.
DOI
|
35 |
Kondapaka SB, Fridman R, Reddy KB (1997). Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer, 70, 722-6.
DOI
|
36 |
Li X, Lewis MT, Huang J, et al (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 100, 672-9.
DOI
|
37 |
Korkaya H, Paulson A, Iovino F, et al (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene, 27, 6120-30.
DOI
|
38 |
Kute T, Lack CM, Willingham M, et al (2004). Development of Herceptin resistance in breast cancer cells. Cytometry A, 57, 86-93.
|
39 |
Lau YK, Du X, Rayannavar V, et al (2014). Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget, 5, 10503-17.
DOI
|
40 |
Liu Y, Chen C, Qian P, et al (2015). Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun, 6, 5988
DOI
|
41 |
Lyon, France (2013). International Agency for Research on Cancer.
|
42 |
Madrid MA, Lo RW (2004). Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res, 6, 593-600.
DOI
|
43 |
Marquez A, Wu R, Zhao J, et al (2004). Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagnostic Molec Path, 13, 1-8.
DOI
|
44 |
Martinelli E, De Palma R, Orditura M, et al (2009). Antiepidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol, 158, 1-9.
|
45 |
Mayo LD, Donner DB (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA, 98, 11598-603.
DOI
|
46 |
Mendez MJ, Green LL, Corvalan JR, et al (1997). Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genetics, 15, 146-56.
DOI
|
47 |
Menard S, Pupa SM, Campiglio M, et al (2003). Biologic and therapeutic role of HER2 in cancer. Oncogene, 22, 6570-8.
DOI
|
48 |
Mendelsohn J (1997). Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res, 3, 2703-7.
|
49 |
Mendelsohn J (2000). Blockade of receptors for growth factors:an anticancer therapy--the fourth annual joseph H burchenal american association of cancer research clinical research award lecture. Clin Cancer Res, 6, 747-53.
|
50 |
Miki Y, Swensen J, Shattuck-Eidens D, et al (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
DOI
|
51 |
Morrison BJ, Schmidt CW, Lakhani SR, et al (2008). Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res, 10, 210.
DOI
|
52 |
Nahta R, Hung MC, Esteva FJ (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 64, 2343-6.
DOI
|
53 |
Nicholson RI, Hutcheson IR, Harper ME, et al (2002). Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci, 963, 104-15.
|
54 |
Nicholson RI, Hutcheson IR, Knowlden JM, et al (2004). Nonendocrine pathways and endocrine resistance:observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res, 10, 346-54.
DOI
|
55 |
Prenzel N, Fischer OM, Streit S, et al (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer, 8, 11-31.
DOI
|
56 |
Normanno N, De Luca A, Bianco C, et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366, 2-16.
DOI
|
57 |
O'Sullivan CC, Bradbury I, Campbell C, et al (2015). Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol, 33, 2600-8.
DOI
|
58 |
Park CY, Tseng D, Weissman IL (2009). Cancer stem celldirected therapies: recent data from the laboratory and clinic. Mol Ther, 17, 219-30.
DOI
|
59 |
Rhodes A, Jasani B, Anderson E, et al (2002). Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol, 118, 408-17.
DOI
|
60 |
Ring A, Wheatley D, Hatcher H, et al (2014). Phase I study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res, 21, 2737-44
|
61 |
Ruddon RW 2007. Cancer Biology, Oxford, Oxford University Press Inc.
|
62 |
Saura C, Garcia-Saenz JA, Xu B, et al (2014). Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 32, 3626-33.
DOI
|
63 |
Schramm A, De Gregorio N, Widschwendter P, et al (2015). Targeted therapies in HER2-positive breast cancer - a systematic review. Breast Care, 10, 173-8.
DOI
|
64 |
Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
DOI
|
65 |
Schulz DM, Bollner C, Thomas G, et al (2009). Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res, 8, 3430-8.
DOI
|
66 |
Sergina NV, Rausch M, Wang D, et al (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinaseinactive HER3. Nature, 445, 437-41.
DOI
|
67 |
Shiovitz S, Korde LA (2015). Genetics of breast cancer: a topic in evolution. Ann Oncol, 26, 1291-9.
|
68 |
Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
DOI
|
69 |
Tai W, Mahato R, Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery. J Control Release, 146, 264-75.
DOI
|
70 |
Twelves CJ, Stebbing J (2012). Being there for women with metastatic breast cancer. a pan-European patient survey. Ann Oncol, 23, 132-.
|
71 |
Valdehita A, Carmena MaJ, Bajo AM, et al (2012). RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Molec Cellular Endocrinol, 348, 241-6.
DOI
|
72 |
Vandevijver MJ, Peterse JL, Mooi WJ, et al (1988). Neu-protein overexpression in breast-cancer - association with comedotype ductal carcinoma insitu and limited prognostic value in stage-II breast-cancer. N Engl J Med, 319, 1239-45.
DOI
|
73 |
Zaha DC (2014). Significance of immunohistochemistry in breast cancer. World J Clin Oncol, 5, 382-92.
DOI
|
74 |
Verma S, Miles D, Gianni L, et al (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine, 367, 1783-91.
DOI
|
75 |
Welslau M, Diéras V, Sohn J-H, et al (2014). Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer, 120, 642-51.
DOI
|